Watch VNDA. Know when insiders buy.
One email the day a filing lands. Free.
VNDA
Vanda Pharmaceuticals Inc.
4.63
−0.18 −3.74%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $279.9MP/E —DIV YIELD —FCF YIELD -51.08%REV TTM $215.7M +6.0%NET INCOME −$274.9MNET CASH —52W 4.32 – 9.56SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $50.5M | −3.9% | — | −$63.8M | −$62.5M | — | -1.04 | −$31.1M | $190K | −$31.3M | Aug 6 |
| Q1 2026 · Mar 31 | $51.7M | +3.4% | — | −$50.2M | −$48.6M | — | -0.82 | −$50.2M | $221K | −$50.4M | Aug 6 |
| Q4 2025 · Dec 31derived | $57.2M | +7.6% | — | −$40.4M | −$141.2M | — | -2.39 | −$29.4M | $102K | −$29.5M | Feb 12 |
| Q3 2025 · Sep 30 | $56.3M | +18.1% | — | −$31.3M | −$22.6M | — | -0.38 | −$31.6M | $161K | −$31.8M | Oct 30 |
| Q2 2025 · Jun 30 | $52.6M | +4.2% | — | −$38.5M | −$27.2M | — | -0.46 | −$15.3M | $299K | −$15.6M | Aug 6 |
| Q1 2025 · Mar 31 | $50M | +5.4% | — | −$41M | −$29.5M | — | -0.50 | −$33.1M | $436K | −$33.6M | Aug 6 |
| Q4 2024 · Dec 31derived | $53.2M | +17.5% | — | −$10.3M | −$4.9M | — | -0.09 | −$1.8M | $214K | −$2M | Feb 12 |
| Q3 2024 · Sep 30 | $47.7M | +22.8% | — | −$11M | −$5.3M | −3986.1% | -0.09 | −$14.6M | $161K | −$14.7M | Oct 30 |
| Q2 2024 · Jun 30 | $50.5M | — | — | −$10.1M | −$4.5M | — | -0.08 | −$6.9M | $108K | −$7M | Oct 30 |
| Q1 2024 · Mar 31 | $47.5M | — | — | −$9.2M | −$4.1M | — | -0.07 | $7.6M | $7K | $7.6M | Oct 30 |
| Q4 2023 · Dec 31derived | $45.3M | — | — | −$7.1M | −$2.4M | — | -0.05 | −$3.7M | $253K | −$4M | Feb 12 |
| Q3 2023 · Sep 30 | $38.8M | — | — | −$6M | $137K | — | 0.00 | −$2M | $24K | −$2.1M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $216.1M | — | −$151.2M | −$220.5M | -102.0% | -3.74 | −$109.4M | $998K | −$110.4M | — | — |
| FY2024 · to Dec 31 | $198.8M | — | −$40.7M | −$18.9M | -9.5% | -0.33 | −$15.8M | $490K | −$16.2M | — | — |
| FY2023 · to Dec 31 | $192.6M | — | −$14M | $2.5M | 1.3% | 0.04 | $12.8M | $383K | $12.4M | — | — |
| FY2022 · to Dec 31 | $254.4M | — | $6.3M | $6.3M | 2.5% | 0.11 | $32M | $679K | $31.3M | — | — |
| FY2021 · to Dec 31 | $268.7M | — | $42.2M | $33.2M | 12.3% | 0.58 | $64.2M | $552K | $63.7M | — | — |
| FY2020 · to Dec 31 | $248.2M | — | $27.2M | $23.3M | 9.4% | 0.42 | $51.8M | $1.8M | $50M | — | — |
Every number comes from Vanda Pharmaceuticals Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.